Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMJEVITA vs ACARBOSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.
Rheumatoid arthritis (moderate to severe active, alone or with methotrexate),Juvenile idiopathic arthritis (moderate to active polyarticular, age ≥2 years),Psoriatic arthritis (active, alone or with DMARDs),Ankylosing spondylitis (active),Crohn's disease (moderate to severe, age ≥6 years),Ulcerative colitis (moderate to severe, adults),Plaque psoriasis (moderate to severe chronic, adults),Hidradenitis suppurativa (moderate to severe, adults),Uveitis (non-infectious intermediate, posterior, and panuveitis, adults and children ≥2 years)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in individuals with impaired glucose tolerance
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Terminal elimination half-life is approximately 2.5 to 3 hours for the parent compound, but the drug acts locally in the GI tract; systemic half-life is not clinically relevant for its pharmacodynamic effect.
Adalimumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via catabolism to small peptides and amino acids.
Acarbose is metabolized exclusively within the gastrointestinal tract, primarily by intestinal bacteria and digestive enzymes. Approximately 35% of the dose is absorbed as metabolites, which are excreted via the kidneys. The parent drug is not significantly metabolized by hepatic enzymes.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Primarily excreted unchanged in feces (approximately 50% of an oral dose) and as metabolites via the gastrointestinal tract; less than 2% of the dose is recovered in urine as active drug or metabolites. Renal excretion is minimal.
Adalimumab is a monoclonal antibody; protein binding is negligible as it is not bound to serum proteins. However, it may bind to soluble TNF-alpha with high affinity.
Negligible to low protein binding; less than 1-2% bound to plasma proteins, primarily albumin.
Volume of distribution (Vd) is approximately 4.7-6.0 L (0.06-0.08 L/kg for a 70 kg adult). This small Vd reflects distribution primarily in the vascular and interstitial spaces, consistent with a large protein.
Volume of distribution is not well defined due to minimal systemic absorption; estimated to be less than 0.3 L/kg, reflecting limited distribution beyond the gastrointestinal lumen.
Subcutaneous bioavailability: 64% (range 50-80%) after 40 mg SC injection. No intravenous formulation is approved; absolute bioavailability determined by comparison to IV administration.
Oral: Systemic bioavailability is very low (approximately 0.5-2%) due to local action in the GI tract and minimal absorption. The drug acts locally in the intestine; systemic levels are negligible.
No dose adjustment required for any degree of renal impairment.
No specific dose adjustment required for GFR ≥25 m L/min; contraindicated in GFR <25 m L/min (creatinine clearance <25 m L/min).
No dose adjustment required for any degree of hepatic impairment.
No specific dose adjustment for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (Child-Pugh class C).
For pediatric patients weighing ≥40 kg: 40 mg subcutaneously every other week; for weight <40 kg: 20 mg subcutaneously every other week.
Not recommended for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment recommended; use with caution due to higher risk of infections.
Initiate at the lowest dose (25 mg 3 times daily); titrate slowly based on tolerance and glycemic control, as elderly patients may have reduced renal function and higher risk of gastrointestinal adverse effects.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), invasive fungal infections, and other opportunistic pathogens. Patients should be tested for latent TB before and during therapy. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
None
Serious infections (bacterial, viral, fungal, including reactivation of HBV),Invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis),Malignancies (lymphoma, leukemia, melanoma, Merkel cell carcinoma, other),Anaphylaxis and allergic reactions,Demyelinating disease (new onset or exacerbation of CNS demyelinating disorders),Hematologic reactions (pancytopenia, aplastic anemia),Congestive heart failure (new onset or worsening),Lupus-like syndrome (autoantibodies, rarely clinical disease),Hepatitis B reactivation,Use with abatacept or anakinra (increased risk of infection)
Risk of hepatotoxicity: rare cases of severe hepatocellular injury, including fulminant hepatitis, reported, especially at higher doses (≥300 mg/day); monitor liver enzymes periodically.,Use with caution in patients with renal impairment (e GFR <25 m L/min/1.73 m²): insufficient data; avoid use.,May cause hypoglycemia when used in combination with sulfonylureas or insulin; treat hypoglycemia with oral glucose (dextrose) rather than sucrose (acarbose inhibits sucrose digestion).,Gastrointestinal adverse effects (flatulence, diarrhea, abdominal pain) are common due to undigested carbohydrate fermentation in the colon; may subside with continued use.,Acute porphyria: acarbose has been associated with acute attacks in susceptible patients.
Known hypersensitivity to adalimumab or any component of the formulation,Active serious infection including sepsis
Hypersensitivity to acarbose or any component of the formulation,Diabetic ketoacidosis,Cirrhosis or significant hepatic impairment,Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Renal impairment (e GFR <25 m L/min/1.73 m²)
No specific food interactions. No dietary restrictions required.
Acarbose delays digestion of complex carbohydrates and sucrose. To reduce gastrointestinal side effects, avoid high-sucrose foods and drinks. Simple sugars like glucose and fructose can still be absorbed and used to treat hypoglycemia. Alcohol may increase the risk of hypoglycemia when combined with acarbose, especially if taken with other antidiabetic agents.
Amjevita (adalimumab) is an Ig G1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and second trimesters, placental transfer is limited. Available data from the OTIS autoimmune diseases in pregnancy study and other cohort studies do not indicate a substantially increased risk of major birth defects or miscarriage with adalimumab exposure during pregnancy. However, there is a potential risk of immunosuppression in the neonate, including increased risk of infections, if the mother is exposed during the second and third trimesters. Infants should not be vaccinated with live vaccines for at least 5 months after maternal last dose.
Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposure. Risk cannot be excluded in first trimester. Second and third trimester: no known fetal risks, but use only if clearly needed.
Adalimumab is excreted in breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.04. Limited data indicate that infants are exposed to less than 1% of the maternal dose, and no adverse effects have been reported in breastfed infants. Because adalimumab is a large protein, it undergoes proteolysis in the infant's gastrointestinal tract and is not systemically absorbed. Therefore, breastfeeding is considered compatible with adalimumab therapy.
Acarbose is excreted into breast milk in negligible amounts due to low oral bioavailability and high molecular weight. M/P ratio not established. Considered compatible with breastfeeding; monitor infant for gastrointestinal effects (e.g., flatulence, diarrhea).
During pregnancy, adalimumab clearance may increase, especially in the third trimester, leading to lower trough concentrations. However, no dose adjustment is routinely recommended due to lack of data showing altered clinical outcomes. Therapeutic drug monitoring is not standard, but if disease activity increases, consider modifying the dose or frequency as per non-pregnant guidelines. Postpartum, clearance returns to prepregnancy levels, so doses should be adjusted back to prepregnancy regimen if modified.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to minimal systemic absorption. Initiate at 25 mg three times daily with meals; titrate based on 1-hour postprandial glucose levels.
AMJEVITA (adalimumab-atto) is a biosimilar to Humira. Administer subcutaneously; rotate injection sites. Do not administer live vaccines. Screen for TB and hepatitis B before initiation. Consider withholding for serious infections. Monitor for allergic reactions and blood dyscrasias.
Acarbose delays carbohydrate absorption by inhibiting alpha-glucosidase in the brush border of the small intestine. It should be taken with the first bite of each main meal. Its efficacy is limited by gastrointestinal side effects (flatulence, diarrhea) due to undigested carbohydrates reaching the colon. Not recommended in patients with inflammatory bowel disease or colonic obstruction. Hypoglycemia from acarbose (rare in monotherapy) must be treated with oral glucose or milk, not sucrose or complex carbohydrates, since their digestion is blocked. Acarbose can cause isolated transaminase elevations; monitor LFTs if symptoms occur.
Store in refrigerator, do not freeze; protect from light.,Inject at room temperature; allow to sit out 15-30 minutes.,Rotate injection sites; avoid tender, bruised, or scarred skin.,Report signs of infection (fever, chills, cough) or allergic reaction immediately.,Do not receive live vaccines while on this medication.,Inform all healthcare providers of your use of AMJEVITA.
Take acarbose with the first bite of each main meal; do not take it between meals.,Common side effects include gas, bloating, and diarrhea, which may improve over time.,If you experience low blood sugar, treat it with glucose tablets, juice, or regular soda, not candy or fruit juice (acarbose blocks their digestion).,Tell your doctor if you develop jaundice or abdominal pain, as liver problems can occur.,This medication is not for weight loss and does not affect insulin secretion.
No interactions on record
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the gut, leading to a reduction in postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity in some patients, potentially increasing the risk of hypoglycemia when combined with acarbose. The interaction is primarily due to additive effects on glucose metabolism, and patients should be monitored for signs of hypoglycemia, particularly during initiation or dose adjustments."
"Chlorothiazide, a thiazide diuretic, can decrease the therapeutic efficacy of acarbose, an alpha-glucosidase inhibitor used for postprandial glycemic control in type 2 diabetes. The hypokalemia induced by chlorothiazide may impair insulin secretion and reduce the glucose-lowering effect of acarbose, potentially leading to elevated postprandial glucose levels. This interaction may necessitate dose adjustments or alternative antihyperglycemic therapy to maintain glycemic control."
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, thereby reducing postprandial hyperglycemia. Selegiline, a selective MAO-B inhibitor at therapeutic doses, can potentiate the hypoglycemic effect of acarbose by an unknown pharmacodynamic mechanism, potentially leading to episodes of hypoglycemia. This interaction is of particular concern in patients with diabetes mellitus who are co-prescribed these agents, as the combined effect on glucose homeostasis may require dose adjustments or enhanced monitoring."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMJEVITA vs ACARBOSE, answered by our medical review team.
AMJEVITA is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.. ACARBOSE is a Alpha-Glucosidase Inhibitor that works by Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMJEVITA and ACARBOSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMJEVITA is: Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.. The standard adult dose of ACARBOSE is: Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMJEVITA and ACARBOSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMJEVITA is classified as Category C. Amjevita (adalimumab) is an IgG1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and seco. ACARBOSE is classified as Category C. Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.